In contrast, applications to B-cell or antibody epitopes remain comparatively limited and often rely on engineered presentation systems—such as cyclic HER-2 peptides stabilized by disulfide bonds or nanoparticle-displayed dengue epitopes—to boost immunogenicity [24,25]. This evidence concerns the gene ERBB2 and dengue disease.